BAT: JP Morgan reinstates coverage with overweight rating; target price 5,300p
BTI•JP Morgan reinstated coverage of BAT with an overweight rating and a 5,300p target price.
Related News
Federal Circuit hears appeal over Acadia's Nuplazid formulation patent
ACAD•
Roche starts Phase II trial of RG6434 in early symptomatic Alzheimer's disease
RHHBY•
Cabot Corp: JPMorgan cuts target price to $68 from $78
CBT•
Dropbox announces upsize and pricing of $1.1 billion convertible notes offering
DBX•
Cushman & Wakefield markets 105-lot Farley residential site in mortgagee sale
CWK•